![IHB_Pharmacy_By_Theihb_(Own_work)_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons IHB_Pharmacy_By_Theihb_(Own_work)_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons](../news/img/healthcare/IHB_Pharmacy_By_Theihb_(Own_work)_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons.jpg)
Revenue in the April to June 30 2022 increased by 7.148 % to $
67.15 billions in in comparison to to $62.67 billions on a year-over-year basis, MCK recorded profits rise of 71.34 % to $5.26, as in comparison to at $3.07 in the prior year financial reporting period.
In contrast to the Q4 Revenues grew by 1.591 % from $66.10 billions and EPS elevated on the another level by 115.69 % from $2.44 per share.
Net earnings of $809.000 millions in the financial first quarter of 2022 increased by 51.78 % from net earnings of $533.000 millions reported in the financial first quarter of 2022 a year ago. Mckesson Corporation also emphasized it's improving profit margins, where net margin rose to 1.2% in financial first quarter of 2022, and operating margin edged up to 1.54%.
Operating earnings, however, rose 82.39% to $1036 millions.
Mckesson Corporation is expected to report next financial results on October 31, 2022.